drugset / Trial / NCT06656221
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the efficacy and safety of Glofitamab combined with Orelabrutinib and Bortezomib in patients with high-risk mantle cell lymphoma
Timeline
- Start
- 2024-12-01
- Primary completion
- 2026-12-01
- Completion
- 2028-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.6 mg/m2 | Intravenous |
| Subject | Glofitamab | Monoclonal antibody | 30 mg | Intravenous |
| Subject | Obinutuzumab | Monoclonal antibody | 2000 mg | Intravenous |
| Subject | Orelabrutinib | Small molecule | 150 mg | Oral |